Cambridge Innovation Technologies Consulting

What Cambridge Innovation Technologies Consulting does

Cambridge Innovation Technologies Consulting (CITC) Ltd is a Cambridge, UK-based private technology consulting and medical research company founded in July 2014 by Luigi G. Occhipinti and Stefano Pluchino to bridge micro/nano-electronics with healthcare. The firm operates as a multidisciplinary R&D house, drawing on a bench of designers, engineers, medical advisors, biologists, material scientists and project managers, and maintains resident research staff at the University of Cambridge Clinical School. Its headcount is in the 1-10 range and its operations are anchored at St. John's Innovation Centre, Cambridge (Reg. No. 09144414), with research activities extending into the Cambridge Biomedical Campus including Addenbrooke's Hospital, the MRC Laboratory of Molecular Biology, and the Wellcome Trust-MRC Cambridge Stem Cell Institute.

CITC's portfolio centres on proprietary platforms in stem cell therapy, wearable medical devices, nano-medicine and drug delivery. iStem4Life™ uses licensed iNSC manufacturing technology from the University of Bonn to reprogram autologous cells for treatment of multiple sclerosis, stroke and spinal cord injuries. Patch4Life™ is a wireless wearable patch integrating Zinergy UK's ultra-thin battery and supercapacitor technology for continuous health and environmental monitoring. humaNase investigates human Asparaginase-like protein 1 (hASRGL1) as a cancer therapeutic alternative to bacterial-derived ASNase. Additional R&D programmes include CUPIDO (cardiovascular nanoparticle drug delivery), B2B (3D organ-on-chip for breast cancer bone metastasis), BENDA (bio-electronic neuro-prosthetics), and the ASMeD platform for application-specific medical devices.

The business operates across three revenue streams: B2B expert design and consultancy services for SMEs, start-ups and industrial research consortia (project-specific, multi-year contracts); R&D project funding from public sources including Innovate UK grants, Horizon 2020, Research England/MedCity, and the European Commission; and prospective technology licensing of its molecular diagnostics, nano-medicine, cell-therapy and advanced-therapy IP portfolios. Customer segments include healthcare and medical institutions (NHS, Cambridge University, King's College London), the medical device industry, and SMEs/start-ups requiring multi-disciplinary R&D expertise. Pricing is custom and not publicly disclosed.

Name

Cambridge Innovation Technologies Consulting

Legal name

Cambridge Innovation Technologies Consulting Limited

Website

https://citc-ltd.co.uk

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Cambridge Innovation Technologies Consulting is a Cambridge-based R&D firm developing stem cell therapies, wearable health-monitoring devices, nano-medicine and drug delivery platforms for healthcare institutions, research consortia and SMEs.

Ownership category

akta.pro rank

Product category

Biotechnology Consulting & Medical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Biotechnology consulting
• Medical device R&D
• Stem cell therapy
• Nanomedicine research
• Wearable health monitoring

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Consultancy Services: Expert design and consultancy services providing business intelligence, due diligence, market analysis, design, testing and industrialization, rapid prototyping, and business development assistance.
2. R&D Project Funding: Funding from government agencies and research programmes including Innovate UK grants, European Commission Horizon 2020 projects, and other collaborative research initiatives.
3. Technology Licensing: Commercialization of proprietary technologies and IP portfolios in molecular diagnostics, nano-medicine, cell-therapies, and advanced therapies through clinical trials and eventual market entry.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Cambridge Innovation Technologies Consulting (CITC) Ltd operates as a technology consulting and medical research company providing expert design and consultancy services to industrial research consortia, SMEs, and start-ups across bio-electronics, smart sensors, nano-medicine, cell-therapies, and drug delivery. The firm develops a portfolio of proprietary R&D platforms including iStem4Life™ autologous stem-cell therapy, Patch4Life™ wearable medical patch, humaNase cancer enzyme, plus EU-funded research projects (CUPIDO, B2B, BENDA, ASMeD) targeting neurological disorders, cancer, and cardiovascular disease.

Product overview

Cambridge Innovation Technologies Consulting (CITC) Ltd operates as a technology consulting and medical research company offering a portfolio of interconnected products and services in healthcare innovation. The core product portfolio includes iStem4Life™ for autologous stem cell therapy, Patch4Life™ for wireless wearable health monitoring, humaNase for cancer therapeutics, and several research projects (B2B, CUPIDO, BENDA) addressing unmet medical needs. These products are supported by the ASMeD technology platform for personalised diagnostics and medical devices, and complemented by expert design and consultancy services. The company bridges micro/nano-electronics with healthcare through multi-disciplinary approaches spanning bio-electronics, smart sensors, and advanced medical solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Patch4Life™: World's Lightest and Smartest 'Wear-and-Forget' Companion Device for Ambient Assisted Living - a medical patch with sensors to measure health and environmental parameters
• iStem4Life™
• humaNase
• CUPIDO
• B2B
• BENDA

Products and services

• iStem4Life™ Stem cell therapy platform for harvesting, reprogramming and storage of autologous stem cells for treatment of neurological disorders including multiple sclerosis, stroke, and spinal cord injuries. Uses licensed technology from University of Bonn to generate induced Neural Stem Cells (iNSCs) through cellular reprogramming without embryonic cells.
• Patch4Life™ Wireless wearable medical patch described as the world's lightest and smartest 'Wear-and-Forget' companion device for ambient assisted living, with sensors for health and environmental parameters (fall detection, glucose levels, context information), wireless communication, and body-adaptable shape for 24/7 personal health monitoring.
• humaNase Cancer therapeutic project investigating the efficacy and therapeutic potential of human Asparaginase-like protein 1 (hASRGL1) as an alternative to bacterial-derived L-asparaginase enzymes for treating cancers such as Acute Lymphoblastic Leukaemia (ALL), with the potential to reduce allergic reactions and toxic side effects.
• B2B (Breast to Bone) 3D Organ-on-Chip Device First-of-its-kind 3D organ-on-chip device project for modelling spontaneous breast cancer metastasis to bone, designed to dissect metastatic complexity and empower high-throughput drug screening to identify metastasis-suppressing therapies.
• CUPIDO Nanoparticle Platform EU-funded project developing innovative bio-inspired hybrid nanoparticles for cardiovascular disease treatment. Nanoparticles are biocompatible, biodegradable, designed for crossing biological barriers, and guidable to the heart for targeted drug delivery.
• BENDA (Bio-electronic Neuro-prosthetic Devices) Bio-electronic Neuro-prosthetic Devices for Active regeneration post CNS injuries, comprising biocompatible and biodegradable smart implants for monitoring and treatment of traumatic diseases affecting the central nervous system, including spinal cord and brain injuries.
• ASMeD (Application Specific Medical Devices) Platform Platform for developing bio-sensors, point of care diagnostics and medical device technologies for personalised medicine, including smart implants and molecular drug delivery systems.
• Expert Design and Support Services Consultancy services including design, testing and industrialisation, rapid prototyping, business intelligence and due diligence, market analysis, and customised design solutions for molecular medicine, personalised diagnostics, and micro/nano-electronics technology development, delivered to industrial research consortia, SMEs, and start-ups.

Quantifiable outcome

• iNSCs generated within 3-4 weeks from patient skin cells
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• King's College LondoncoreStrategic or Co-development Partner · 1 November 2019Research partnership as part of Collaborate to Innovate programme (funded by Research England, managed by MedCity). Combines King's expertise in GMP mesenchymal stem cell manufacturing with CITC's iNSC technology to develop SOPs for scaling up iNSC production for progressive MS therapy. Stefano Pluchino (CSO) and Professor Francesco Dazzi leading respective teams.
• RESTORE Health by Advanced Therapies ConsortiumflagshipStrategic or Co-development Partner · 4 March 2019Selected as one of 2 finalists competing to become European Commission billion-euro flagship science initiative in Health and Life Sciences. Five Research and Innovation Action modules addressing advanced therapies. CITC and University of Cambridge represented as committed stakeholders.
• B2B Consortium (European Horizon 2020 FET Open)coreStrategic or Co-development Partner · 30 July 2018Horizon 2020 FET Open project (Project No. 801159) developing 3D organ-on-chip device for breast cancer bone metastasis. Coordinated by CNR (Italy), with partners including University of Basel, Maastricht University, React4Life, IN Srl, Erasmus MC, BET solutions (Greece).
• CUPIDO Consortium (12 partners)coreStrategic or Co-development Partner · 1 October 2017EU-funded project (GA No 720834) developing nanoparticle-assisted drug delivery for cardiovascular disease. 12 partners from Italy, Germany, Norway, UK, Greece, France and Luxembourg. CITC coordinates project exploitation and regulatory pathways. Coordinated by Italian National Research Council (CNR).
• Zinergy UKcoreTechnology or Integration · 19 September 2017Collaboration on Patch4Life™ platform (Re-Patch project) to integrate Zinergy's ultra-thin film battery and supercapacitor technology into CITC's smart patch device for 24/7 autonomous continuous operation. Funded by Innovate UK under 'Emerging and Enabling Technology' call.
• Provendis GmbHcoreOEM/ Whitelabel/ Licensing Partner · 21 February 2017Non-exclusive license agreement with technology transfer agency of 27 universities of North Rhine-Westphalia including University of Bonn for manufacturing technology of autologous iNSCs from adult cells. Prof. Frank Oliver Stefan Edenhofer is the inventor.
• University of CambridgecoreStrategic or Co-development PartnerOngoing research collaboration with Department of Clinical Neurosciences and Wellcome Trust-MRC Cambridge Stem Cell Institute. CITC has resident research staff located within Clinical School. Stefano Pluchino holds positions as University Reader in Regenerative Neuroimmunology.
• CNR (National Research Council, Italy)coreStrategic or Co-development PartnerCoordinator of B2B and CUPIDO projects. Italian National Research Council leads these EU-funded initiatives involving multiple international partners.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• TTP plc (The Technology Partnership): UK-based technology consulting and product development firm with significant healthcare and medical device practice. Comparable to CITC's role in bridging advanced engineering (micro/nano-electronics) with medical applications and developing novel devices through to commercialization.
• Mimetas: Dutch organ-on-chip company developing 3D tissue models for drug discovery and disease modeling. Directly comparable to CITC's B2B program (3D organ-on-chip for breast cancer metastasis) addressing similar applications in high-throughput drug screening.
• Emulate Inc: US-based organ-on-chip technology company with broader platform. Comparable to CITC's B2B organ-on-chip program and similar focus on recapitulating physiological complexity for drug screening applications.
• Plasticell: UK-based stem cell biotechnology company specializing in cell reprogramming and regenerative medicine. Directly comparable to CITC's iStem4Life program focusing on stem cell-based therapies for neurological and other disorders.
• Huma Therapeutics: UK-based digital health and remote patient monitoring company. Comparable to CITC's Patch4Life platform in wearable health monitoring and remote patient management, both targeting active/passive biosensor-driven health tracking.
• RoslinCT: UK-based cell therapy contract development and manufacturing organization (CDMO). Comparable to CITC's iNSC manufacturing focus and therapeutic cell therapy development pipeline, with overlapping customer base in cell therapy biotech.
• Cambridge Consultants: UK-based technology and innovation consultancy headquartered in Cambridge with deep healthcare and life sciences practice. Directly comparable to CITC's consulting-led model, multi-disciplinary engineering expertise, and product development services for medical device and biotech clients.

Broad incumbents

• BlueRock Therapeutics: Large, well-funded cell therapy company (acquired by Bayer for up to $1B) focused on induced pluripotent stem cell-derived therapeutics. Comparable therapeutic modality (engineered cell therapies) to CITC's iStem4Life, but with significantly greater capital and clinical resources.
• iRhythm Technologies: US-based digital healthcare company with FDA-cleared wearable cardiac monitoring patch (Zio). Closest commercial comparable to CITC's Patch4Life wearable platform, demonstrating the market for 'wear-and-forget' biometric monitoring.
• PA Consulting: Global consulting firm with extensive life sciences and healthcare practice. Comparable to CITC's consulting services arm with similar multi-disciplinary expertise and innovation/R&D support offerings for life sciences clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CITC_Ltd
• Facebookfacebook.com/InnovationTechnologiesConsulting
• LinkedInlinkedin.com/company/citc-cambridge

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cambridge Innovation Technologies Consulting